JP2019528753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528753A5 JP2019528753A5 JP2019516383A JP2019516383A JP2019528753A5 JP 2019528753 A5 JP2019528753 A5 JP 2019528753A5 JP 2019516383 A JP2019516383 A JP 2019516383A JP 2019516383 A JP2019516383 A JP 2019516383A JP 2019528753 A5 JP2019528753 A5 JP 2019528753A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- items
- vaccinia virus
- oncolytic vaccinia
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700618 Vaccinia virus Species 0.000 description 159
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 130
- 102000055207 HMGB1 Human genes 0.000 description 130
- 108700010013 HMGB1 Proteins 0.000 description 130
- 101150021904 HMGB1 gene Proteins 0.000 description 130
- 230000000174 oncolytic effect Effects 0.000 description 126
- 150000007523 nucleic acids Chemical class 0.000 description 80
- 102000039446 nucleic acids Human genes 0.000 description 68
- 108020004707 nucleic acids Proteins 0.000 description 68
- 238000000034 method Methods 0.000 description 53
- 239000008194 pharmaceutical composition Substances 0.000 description 51
- 206010028980 Neoplasm Diseases 0.000 description 47
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 30
- 201000011510 cancer Diseases 0.000 description 22
- 230000035772 mutation Effects 0.000 description 20
- 241000700605 Viruses Species 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 238000011374 additional therapy Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 108010003272 Hyaluronate lyase Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 230000008707 rearrangement Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 101100272669 Aromatoleum evansii boxA gene Proteins 0.000 description 3
- 101100272670 Aromatoleum evansii boxB gene Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 102000053637 human HMGB1 Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000710185 Mengo virus Species 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 241000837158 Senecavirus A Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 239000012635 anticancer drug combination Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662397523P | 2016-09-21 | 2016-09-21 | |
| US62/397,523 | 2016-09-21 | ||
| PCT/US2017/052746 WO2018057755A1 (en) | 2016-09-21 | 2017-09-21 | High mobility group box i mutant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528753A JP2019528753A (ja) | 2019-10-17 |
| JP2019528753A5 true JP2019528753A5 (enExample) | 2020-11-12 |
Family
ID=61691108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516383A Pending JP2019528753A (ja) | 2016-09-21 | 2017-09-21 | 高移動度グループｂｏｘｉ突然変異体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11065286B2 (enExample) |
| EP (1) | EP3515419A4 (enExample) |
| JP (1) | JP2019528753A (enExample) |
| KR (1) | KR20190059297A (enExample) |
| CN (1) | CN110022867A (enExample) |
| AU (2) | AU2017332367B2 (enExample) |
| WO (1) | WO2018057755A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| IL319942A (en) | 2016-11-02 | 2025-05-01 | Evans David | Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| CN109913422A (zh) * | 2017-12-13 | 2019-06-21 | 苏州康聚生物科技有限公司 | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 |
| AU2019208892B2 (en) * | 2018-01-19 | 2022-02-03 | Kolon Life Science, Inc. | Recombinant vaccinia virus and pharmaceutical composition comprising same |
| CA3099330A1 (en) * | 2018-05-02 | 2019-11-07 | Tonix Pharma Holdings Limited | Synthetic chimeric vaccinia virus |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| JP2022545191A (ja) * | 2019-08-29 | 2022-10-26 | バイオノックス インコーポレイテッド | 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物 |
| JP2023552289A (ja) | 2020-11-19 | 2023-12-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法 |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| IL320318A (en) * | 2022-10-19 | 2025-06-01 | Kalivir Immunotherapeutics Inc | Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
| WO2026107113A1 (en) | 2024-11-12 | 2026-05-21 | Calidi Biotherapeutics (Nevada), Inc. | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014314A2 (en) | 2002-08-12 | 2004-02-19 | David Kirn | Methods and compositions concerning poxviruses and cancer |
| GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
| AU2004272607B2 (en) | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| WO2009054996A2 (en) * | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| EP2617426B1 (en) | 2010-09-17 | 2016-08-10 | Japan Science and Technology Agency | Inhibitor of hmgb protein-mediated immune response activation |
| EP2697368B1 (en) | 2011-04-15 | 2019-06-05 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| EP3358011B1 (en) * | 2011-04-26 | 2020-03-04 | StemRIM Inc. | Peptide for inducing regeneration of tissue and use thereof |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| ES2847305T3 (es) * | 2013-08-22 | 2021-08-02 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapias inmunooncolíticas |
-
2017
- 2017-09-21 JP JP2019516383A patent/JP2019528753A/ja active Pending
- 2017-09-21 KR KR1020197011336A patent/KR20190059297A/ko not_active Withdrawn
- 2017-09-21 EP EP17853903.7A patent/EP3515419A4/en active Pending
- 2017-09-21 WO PCT/US2017/052746 patent/WO2018057755A1/en not_active Ceased
- 2017-09-21 US US16/335,515 patent/US11065286B2/en active Active
- 2017-09-21 AU AU2017332367A patent/AU2017332367B2/en not_active Ceased
- 2017-09-21 CN CN201780071852.1A patent/CN110022867A/zh active Pending
-
2021
- 2021-06-01 US US17/335,430 patent/US20210338754A1/en active Pending
-
2022
- 2022-01-12 AU AU2022200169A patent/AU2022200169B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shaw et al. | Immunology of adenoviral vectors in cancer therapy | |
| CN109152815B (zh) | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 | |
| JP6912199B2 (ja) | 免疫腫瘍溶解療法 | |
| Hamada et al. | Efficient delivery and replication of oncolytic virus for successful treatment of head and neck cancer | |
| JP2023089171A (ja) | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 | |
| Dong et al. | Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages | |
| TW201722477A (zh) | 藉由組合療法治療固態或淋巴腫瘤的方法 | |
| JP2007020586A5 (enExample) | ||
| JP2019501670A5 (enExample) | ||
| Lee et al. | Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies | |
| CN109415706A (zh) | 假型化的溶瘤弹状病毒及其在组合治疗中的应用 | |
| Yin et al. | Strategies for engineering oncolytic viruses to enhance cancer immunotherapy | |
| KR20190091299A (ko) | 암 치료에 사용하기 위한 약학적 조성물 | |
| Altinoz et al. | Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential | |
| JP7772429B2 (ja) | 抗膵臓がんのワクチン、及びその医薬的使用 | |
| US9526779B2 (en) | Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus | |
| Yang et al. | Oncolytic virus for cancer immunotherapy | |
| CN113117088B (zh) | 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用 | |
| JP2020531437A (ja) | ｈａＮＫセツキシマブ併用及び方法 | |
| US20230321165A1 (en) | Medicament for treating cancer, immunostimulant, and method for screening for anti-cancer substance | |
| WO2003092708A1 (en) | Antitumor agents with the use of hsv | |
| CN116724110A (zh) | 重组溶瘤病毒及其构建方法和用途 | |
| TWI666321B (zh) | 用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構 | |
| Guinness | Oncolytic Virus Immunotherapy: Development and Potential for Cancer Treatment | |
| US20220296702A1 (en) | Pharmaceutical compositions comprising oncolytic herpes simplex virus for systemic administration |